Phase III Relaxin Trial Did Not Reach Primary Endpoint.
Relaxin is of no value for the treatment of scleroderma.
"Scleroderma has again proven to be an extremely difficult disease for which to develop a therapeutic treatment." Connetics 10-8-00.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: